Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs
This case highlights a young CML patient who achieved a major molecular response (MMR) after just four months with a subtherapeutic dose of asciminib. The patient could not tolerate full-dose asciminib, or the full dose of two previous tyrosine kinase inhibitors (TKI) due to myelotoxicity, but blood counts recovered rapidly upon TKI suspension and reduced dosing enabled sustained treatment. This is the second reported case of the use of 20 mg QD asciminib, four times below the recommended dose, and the first to demonstrate efficacy at this dose. The study emphasizes asciminib's potential for overcoming treatment challenges associated with multi-resistant/intolerant CML patients.
Authors
- Ruth Stuckey (ORCID: https://orcid.org/0000-0001-6955-2290)
- Alejandro Morales Curbelo
- Adrián Segura-Díaz (ORCID: https://orcid.org/0000-0002-2070-3227)
- Leslie González Pinedo
- Laura Navarrete Bullón
- Cristina Bilbao (ORCID: https://orcid.org/0000-0002-4796-1445)
- Álvaro Veiga Vaz
- María Teresa Gómez‐Casares (ORCID: https://orcid.org/0000-0003-0505-5126)
- M. Torres Ochando (ORCID: https://orcid.org/0000-0001-5465-3355)
- Asunción Borrero Borrego (ORCID: https://orcid.org/0000-0002-0293-5614)
- Javier Rodríguez (ORCID: https://orcid.org/0000-0002-4862-4088)
- María del Mar Perera
- Carlos Rodríguez‐Medina (ORCID: https://orcid.org/0009-0007-8891-5262)
- Violeta Vidal Ballester
Institutions
- Universidad de Las Palmas de Gran Canaria (ES)
- Hospital Universitario de Gran Canaria Doctor Negrín (ES)
- Instituto de Investigación Biomédica de Salamanca (ES)
- University of Pennsylvania (US)
Publication Details
- Journal
- Annals of Hematology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1007/s00277-025-06339-5
- Citations
- 1
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77